Shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) ended Wednesday session in red amid volatile trading. The shares closed down -0.053 points or -9.23% at $0.517 with 7.94 million shares getting traded. Post opening the session at $0.60, the shares hit an intraday low of $0.48 and an intraday high of $0.63 and the price vacillated in this range throughout the day. The company has a market cap of $83.92 million and the numbers of outstanding shares have been calculated to be 113.74 million shares.
Northwest Biotherapeutics, Inc (NWBO) discovers and develops immunotherapy products to treat cancer in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patients own immune system to attack cancer. The companys products include DCVax-L, which is under Phase III brain cancer trial for treating brain cancer; DCVax-Direct that is under Phase I/II clinical trial for various types of inoperable solid tumor cancers; and DCVax-Prostate, which is under Phase III for prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
Shares of CVS Health Corp (NYSE:CVS) ended Wednesday session in red amid volatile trading. The shares closed down -1.49 points or -1.64% at $89.44 with 7.94 million shares getting traded. Post opening the session at $90.75, the shares hit an intraday low of $89.33 and an intraday high of $91.13 and the price vacillated in this range throughout the day. The company has a market cap of $94.21 billion and the numbers of outstanding shares have been calculated to be 1.07 billion shares.
CVS Health Corp (CVS) on Sept. 14, 2016 announced that the opioid overdose-reversal medication naloxone is now available for patients without a prescription at all CVS Pharmacy locations in Washington. Under a collaborative agreement with a physician in the state, CVS pharmacists can exercise prescriptive authority to dispense the medication. In addition to Washington, CVS Pharmacy locations in 30 other states are able to dispense naloxone to patients without an individual prescription. The company’s move to increase access to naloxone builds on its other efforts to reduce drug abuse, including prevention education and safe drug disposal.
“Naloxone is a safe and effective antidote to opioid overdoses and by expanding access to this medication in our Washington pharmacies for patients without a prescription, we can help save lives,” said Tom Davis, RPh, Vice President of Pharmacy Professional Practices at CVS Pharmacy. “We are dedicated to helping the communities we serve address and prevent drug abuse and we are expanding access to naloxone to give more people a chance to get the help they need for recovery.”
“The impact of drug abuse has been felt by our families and friends across the state of Washington. It is a crisis that impacts people of every age, income level and race and involves prescription medications and illegal drugs,” Governor Jay Inslee said. “I commend CVS for making the lifesaving opioid overdose reversal drug Naloxone available directly from a pharmacist, and for providing safe disposal options for unwanted medications. To address this epidemic we need the public and private sector working together on options such as this for our communities. Please visit www.stopoverdose.org to learn how to prevent and respond to an opioid overdose.”